United Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Roger Song from Jefferies maintained a Buy rating on the stock and has a $564.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roger Song has given his Buy rating due to a combination of factors involving United Therapeutics’ legal positioning and potential market advantages. The ongoing patent litigation concerning the ‘327 patent, specifically the dependent claims, plays a significant role in this assessment. If the court finds these claims to have patentable weight, United Therapeutics could effectively block competitors like Yutrepia or seek damages, which would strengthen its market position.
Furthermore, the interpretation of the Bayer Pharma v. Mylan case could favor United Therapeutics if the dependent claims are deemed to add meaningful limitations, similar to cases like Allergan and L’Oréal. This potential legal advantage, coupled with the company’s ability to enforce its patent rights, underpins the Buy rating as it suggests a favorable outcome that could enhance United Therapeutics’ competitive edge and financial performance.
In another report released yesterday, UBS also reiterated a Buy rating on the stock with a $580.00 price target.
Based on the recent corporate insider activity of 166 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.